Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Technology, Application The global genome editing will witness a robust CAGR of 17.33%, valued at $5.06 billion in 2021, and expected to appreciate and reach $21.36 billion by 2030, confirms Strategic Market Research. Genome editing or gene editing or genome engineering is the process through which genetic materials are modified in an organism's DNA to observe the changes that are occurring and aim to improve the understanding of the diseases and conditions such as single nucleotide polymorphisms (SNPs), cystic fibrosis (CF), hemophilia, and sickle cell disease that are caused by genetic defects. Genome editing aims to find treatments for diseases, improve health in plants, improvise the efficacy of Endogenous gene labeling, embryo genome editing, Targeted transgene addition, gene editing tools, and prevention of endemic diseases such as malaria and diarrhea. The market for gene editing will see tremendous growth in the forecasted period. With the discovery of CRISPR (Clustered regularly interspaced short palindromic repeats), which won the Nobel Prize in Chemistry in 2020, the applications for gene editing will further ensure enhanced growth of the market for many years to come. In a trial conducted in 2020, CRISPR was used to modify genes by chromosome rearrangement in patients with multiple myeloma and showed that the growth of the tumor stopped in one patient, despite later growing back. The observation from the trial showed the outlook and perspective for the use of the CRISPR gene editing tool in cancer treatment. SMR’s study further showed that the CRISPR technology equipped with Pro-code (referred to as signal paths in reverse-genetic screenings) is almost 75% more efficient in breast cancer screening in comparison to the other technologies. In the agricultural sector, white button mushrooms underwent an experiment that removed the enzyme that caused mushrooms to blemish and brown. By applying gene therapy, the genes that control polyphenol oxidase (PPO) were modified, and the enzyme which causes browning and the effect of browning got reduced by 30%. The experiment resulted in getting clearance from the FDA, meaning that mushrooms with the edited gene could now be grown without FDA oversight. Thus, with increasing research in different fields of agriculture, healthcare, and animal gene editing, the market for genome editing is set to see a phase of prolonged growth in the years to come. Key Industry Drivers - Higher Occurrences of Genetic Disorders (I.E., Single-Gene Disorders, Increased Investment in The Sector). Those diseases which occur due to mutations (pathogenic variant which is caused by a detrimental change or variation to a respective gene) which affects the genes or when one possesses the incorrect amount of genetic material are referred to as genetic disorders. According to the US Genetic and Rare Disease Information Center, approximately one out of ten (nearly thirty million people) in the US have a genetic or rare disease. Numbers from a WHO report suggest that in approximately 2-5% of all live births, a genetic defect or congenital abnormality is detected. These births account for approximately 30% of admissions in pediatric wards in hospitals. According to the WHO, congenital malformations are the primary cause of infant mortality in the UAE and among the main causes of infant mortality in Qatar, Oman, Bahrain, and Kuwait. Thus, with an increasing prevalence of genetic disorders globally, the need for solutions using genome editing and drug development is the need of the hour. Investments in the sector have seen phenomenal growth, especially since the discovery of CRISPR technology. In 2021, the genome editing sector raised investments exceeding USD 1.3 billion, with 18 deals involving CRISPR technology in 2021. Mammoth Bioscience companies received the highest amount of funding, with the aim to expand their facilities and technologies into developing the next generation of CRISPR technology. Thus, with the increasing investments by firms to improve upon existing technologies, the genome editing market is set to grow phenomenally in the years to come. Opportunities - Increasing Applications in Cancer Research, Genetic Engineering of Plants According to WHO, the number of deaths caused by cancer in 2020 was approximately 10 million, making it one of the leading causes of worldwide fatalities. Lung Cancer is the major cause of mortality worldwide, with almost 1.81 Million per year, followed by Rectum and Colon Cancer (around 916k), liver cancer (close to 830k), stomach cancer (769 k deaths), and breast cancer (6,85,000 deaths out of which more than 90% are women). This provides immense opportunities for research across the medical and bio-scientific fields. Research from studies has shown that the use of the CRISPR/Cas9 system has been effective in preventing cancer cells from growing. Further research into somatic cell treatment provides opportunities to further aid the treatment and prevention of cancer. The application of genome editing is widely applicable in the field of plants and has been used for the commercial growth of agricultural crops. An International Service for the Acquisition of Agro-biotech Applications (ISAAA) report states that in India, Bt cotton is 80% of the total of 12 million hectares of cotton grown. As per FDA findings, on average, approximately 95% of five crops - corn, soybean, cotton, sugar beets, and canola grown in the US were using crop seeds developed by plant genome editing. With crops being commercially grown using GM seeds, further research in the field of plant genetic engineering would result in newer applications that would benefit botanists and agriculturists. Thus, the market for genome editing would significantly grow and cater to ample opportunities over the upcoming time period. Restraints The major restraints of the genome editing market are long approval periods by authorities on clearing GM products and the widespread misinformation regarding genetically engineered products. Market Analysis Of Different Segments Covered in the Report Based on Product and Service Consumables Reagents Services Software Systems Based on Technology Antisense CRISPR TALEN ZFN Other technologies Based on Application Cell Line Engineering Diagnostic applications Drug discovery and development Plant Genetic Engineering Animal Genetic Engineering Other applications Based on End-user Academic Research Institutes Biotechnology companies Government Research Institutes Pharmaceutical companies Regional Coverage Analysis North America USA Canada Mexico Europe France Germany Italy Spain United Kingdom Rest of Europe Asia Pacific Australia China India Japan South Korea Vietnam Rest of Asia Pacific Latin America, Middle East, and Africa Argentina Brazil Nigeria Qatar Saudi Arabia South Africa UAE Rest of LAMEA Segments Analysis & Insights On the basis of products and services, reagents and consumables dominated the market primarily due to the volume of sales achieved through their extensive use in the industry. Reagents such as Azidothymidine, abscisic acid, Brefeldin A, and nocodazole are extensively used across labs and institutes which have genetic engineering facilities. With an increasing number of laboratories, hospitals, and academic institutions, the use of reagents and consumables will increase, thereby further solidifying their market growth. CRISPR dominated the technology segment due to increased application in the fields of biotechnology, agriculture, and healthcare. CRISPR/Cas9 is being studied extensively to develop solutions for critical diseases such as Huntington's disease and human immunodeficiency virus (HIV). Research has shown that Huntington's disease is caused by a mutant protein, and by using CRISPR/Cas9 in mouse models, the production of the mutant protein was reduced by approximately 90%. Studies have shown that CRISPR/Cas9 has also been used to effectively remove the receptors that cause viral infections. FTO is one of the genes that have strongly been linked to obesity. Researchers have shown that using the knock-in techniques of CRISPR/Cas9, the FTO-linked cells are replaced by adipocyte precursor cells. Thus, with several hundred studies and experiments being conducted worldwide using CRISPR technologies, we will see the continued domination of the technology in the segment. Crisper is a technology used to edit genes, and it's a way of finding a particular bit of DNA inside a cell. After that, it alters that specific DNA. Crisper is also used for other things, for instance, turning genes on or off without changing their sequence. Crisper-Cas parts are altered to emit color or fluorescent signals in reaction to negative or positive detection of the target genetic sequence, generally an indication of a disease. The gene editing characteristic of Crispr is used in diagnostic and therapeutics of cancer, neurodegenerative disorders, blindness, genetic disease, etc. Cell line engineering has the most dominant market share due to its widespread application in the fields of biology, pharmacology, and agriculture, among other fields. Cell line engineering is the process by which a cluster of cells is created from a specific type of tissue (like those from a specific organ or the xylem of a plant) to ensure uniformity in the resultant tissue. Cell lines have been extensively used in drug development, producing vaccines, synthesizing proteins, and artificial tissue generation. Due to extensive research in the field, over 36,000 cell lines have been generated for use in healthcare, academia, and pharmacogenomics. Thus, with extensive research opportunities available using cell lines, the market would see a period of established growth in the years to come. Cellular engineering applies methods and principles of engineering to the complications of molecular and cell biology of both basic and applied nature. As biomedical engineering shifted from the tissue and organ level to the sub-cellular & cellular level, cellular engineering has come up as a new revolution. Cell culture technology is the ability to grow and generate living cells in the artificial environment of a lab. Top companies involved in stem research & regenerative medicine are growing markets in the life science sector and working hard in order to make a difference in the stem-cell field. Amgen, a worldwide leader in biotechnology, has paired up with CCRM, a Canada -based company, to commercialize regenerative medicine-based technologies and gene therapies and cells. Gilead, a biopharmaceutical company, has produced a stem cell therapy Yescarta, a CAR-T cell therapy for blood cancer. Yescarta assists a patient immune system in fighting the disease. Vertex and its partner CRISPR Therapeutics have produced exa-cel (exagamglogene autotemcel, earlier known as CTX001. It is a one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia. In the mids of 2022, Vertex Pharmaceutical expanded its regenerative medicine portfolio with $320 million and acquired Viacyte and its stem cell-based diabetes treatment. Warren Grayson, the professor of bioengineering, has been putting efforts to regenerate bone-like tissue with the assistance of natural anatomical structure, the living tissue that grows and changes with the patient and is made from the patient's genetic material so the chances of rejection are close to zero, and they have experimented in mice and pigs. By end-user, biotechnology and pharmaceutical companies shared the dominance of the market with nearly equal market shares. The application of gene editing by both is aimed at developing new therapeutics for use in the healthcare sector. Additionally, biotech companies also use gene editing to create GM seeds and transgenic animals. China recently approved the usage of four varieties of GM corn and three varieties of GM soybean after a ten-year trial period. Australia has grown over 21% of its canola using GM seeds. Thus, with increased research in the field due to investments by companies, the biotech and pharmaceutical companies will continue to dominate the end-user segment. The North American region spearheaded the genome editing market due to the presence of several headquarters and R&D centers of biotech and pharmaceutical companies; additionally, the healthcare infrastructure and agriculture infrastructure, which quickly adopt newly developed technologies, further help the region maintain its supremacy. As per records, over 6,600 registered biotechnology companies are present in the US, alongside over 2,000 pharmaceutical companies. Canada has over 1,000 registered biotechnology companies and more than 50 brand-name pharmaceutical companies. Thus, with policies that favor businesses to thrive, the number of biotechnology and pharmaceutical companies will continue to proliferate in the region, thereby bolstering overall regional growth. Genome Editing Market Report Coverage Report Attribute Details Period of Forecast 2021 - 2030 The Market size value in 2021 USD 5.06 billion The Revenue forecast in 2030 USD 21.39 billion Growth rate CAGR of 17.33 % The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Product and service, application, technology, end-users, and region. By Product and Service Consumables, Reagents, Services, Software, and Systems. By Application Cell Line Engineering, Diagnostic applications, Drug discovery and development, Plant Genetic Engineering, Animal Genetic Engineering, and Other applications. By Technology Antisense, CRISPR, TALEN, ZFN, and Other technologies. By Region North America, Europe, Asia-Pacific, and LAMEA By end-users Academic Research Institutes, Biotechnology companies, Government Research Institutes and Pharmaceutical companies. Country Scope USA, Canada, India, Vietnam, China, Russia, Australia, The Netherlands, France, Germany, Singapore, and Switzerland. Company Usability Profiles Agilent Technologies, Beam Therapeutics, Beren Therapeutics, Bluebird Bio, Caribou Biosciences, Inc., Cellectis S.A, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, Eurofins Scientific, GenScript, Horizon Discovery Group plc., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Precision Biosciences, Recombinetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Inc., Synthego, Tecan Life Sciences, Thermo Fisher Scientific Inc., Transposagen Biopharmaceuticals, and Vigene Biosciences. Global Genome Editing Market Competitive Landscape Analysis Beam Therapeutics Agilent Technologies Bluebird Bio Caribou Biosciences Beren Therapeutics Cellectis S.A Editas Medicine Creative Biogene Eurofins Scientific CRISPR Therapeutics Intellia Therapeutics Horizon Discovery Group plc. Integrated DNA Technologie Lonza GenScript Merck OriGene Technologies New England Biolabs Precision Biosciences PerkinElmer Regeneron Pharmaceuticals Recombinetics Synthego Sangamo Therapeutics Thermo Fisher-Scientific Vigene Biosciences Tecan Life-Sciences Trans-posagen Bio-pharmaceuticals Recent Developments: In July 2022, a research team at the University of California, San Diego, found a new technique to 'repair' genetic defects. By using “soft” CRISPR, the scientists were able to target only a single strand of DNA to develop red-eye color in fruit flies. Their objective is to further carry out experiments to make it viable to treat and cure human genetic diseases. In July 2022, Verve Therapeutics' clinical trial on a patient involved the injection of a gene-editing drug to lower LDL cholesterol. The patient suffered from cardiac disease and had an extremely high cholesterol level. The aim is to conduct further trials to prevent high LDL levels, thereby preventing cardiovascular diseases. If the drug works, it would be offered as a one-time shot to lower the high LDL levels in patients and address the primary cause of death in the US -heart disease. In July 2022, a study found that Nothobranchius furzeri (N. furzeri), commonly called the African turquoise killifish, can be used as an organism to study vertebral aging. The fish was modified using the gene knockout method to further make them viable for studies on aging and embryonic diapause. These methods reduce the experiment duration and facilitates rapid identification of the genes. In July 2022, the president of Italy's Commission for Agriculture presented a law that would enable genome editing companies to provide seeds to ensure higher yield and lower water consumption to fight with the drastic climate changes. The matter would be deliberated in the parliament and is expected to become an act primarily benefitting farmers and agro-biotech companies. In May 2022, the English parliament introduced a Bill that would enable the release of genetically edited products. The Genetic Technology (Precision Breeding) Bill aims to benefit companies, farmers, and consumers. The bill is currently under the report stage in the House of Commons. In July 2022, researchers at the Indiana Center for Regenerative Medicine and Engineering developed a technology that is able to regenerate tissue in a live body. Tissue Nano transfection (TNT) was developed using gene editing technology and aimed to assist in the treatment of crushed nerves, diabetic retinopathy, injured legs, and brains affected by stroke. Products Developed by the Major Companies: Name Feature Key Player SureGuide gRNA Control kit Well-documented control materials, quality assurance assessment, determining DNA cleavage efficiency. Agilent Technologies SCC109 AC16 Human Cardiomyocyte cell line. It can be serially passaged and differentiated after being cultured in the mitogen-free medium. Sigma Aldrich (Merck) NTLA - 3001 & NTLA - 2003 Steady and continuous expression of A1AT protein knockout of mutant gene SERPINA1. Intellia Therapeutics TaqMan Gene Expression Assays Gold Standard reproducibility, specificity, and sensitivity detect almost all gene transcripts available for more than 30 species and select pathogens. ThermoFisher Scientific Frequently Asked Question About This Report Which segment accounted for the largest genome editing market share? The technology segment accounted for the largest share of the market. Which technology segment accounted for the largest share in the market? CRISPR technology accounted for the largest share in the technology segment of the genome editing industry. What is the best gene-editing company? CRISPR Therapeutics AG is considered the best company for gene editing. Which delivery method held the highest share in the market? The ex-vivo delivery method held the highest share at more than 57% of the market. How big is the genome editing market? The global genome editing market size was $5.06 billion in 2021 and is expected to reach a value of $21.36 billion by 2030. What is the genome editing market growth? The global genome editing market is expected to grow at a compound annual growth rate (CAGR) of 17.33% from 2021 to 2030 to reach USD 21.36 billion by 2030. What is the size of the North American market? The North American market was worth USD 1.63 billion. Is gene editing well for the economy? Gene editing is extremely beneficial to the economy as it improves agricultural yield, increases lifespan by treating diseases, and promotes further scientific research in various fields Sources https://www.mckinsey.com/industries/life-sciences/our-insights/whats-ahead-for-biotech-another-wave-or-low-tide https://www.pharmamedical.ca/.well-known/captcha/?r=%2Fcanadian-biotechnology-company-list%2F https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437870/ https://rarediseases.info.nih.gov/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Genome Editing Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Genome Editing Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Product and Service Business Analysis 4.4.1 market, By Product and Service, 2021 - 2030 (USD Million) 4.5 By Technology Business Analysis 4.5.1 market, By Technology, 2021 - 2030 (USD Million) 4.6 End-user Business Analysis 4.6.1 market, By End-user, 2021 - 2030 (USD Million) 4.7 Application Business Analysis 4.7.1 market, By Application, 2021 - 2030 (USD Million) 4.8 Value Chain Analysis 4.9 Market Variable Analysis 4.9.1 Market Drivers Analysis 4.9.2 Market Restraints Analysis 4.10 Business Environment Analysis Tool 4.10.1 market PEST analysis 4.10.2 market Porter’s analysis 4.11 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product and Service 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product and Service Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Consumables 7.3.1. Consumables market, 2021 - 2030 (USD Million) 7.4. Reagents 7.4.1. Reagents market, 2021 - 2030 (USD Million) 7.5. Services 7.5.1. Services Market, 2021 - 2030 (USD Million) 7.6. Software 7.6.1. Software market, 2021 - 2030 (USD Million) 7.7. Systems 7.7.1. Systems market, 2021 - 2030 (USD Million) 8. Market: By Technology Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Antisense 8.3.1. Antisense Market, 2021 - 2030 (USD Million) 8.4. CRISPR 8.4.1. CRISPR market, 2021 - 2030 (USD Million) 85. TALEN 8.5.1. TALEN market, 2021 - 2030 (USD Million) 85. ZFN 8.5.1. ZFN market, 2021 - 2030 (USD Million) 85. Other technologies 8.5.1. Other technologies market, 2021 - 2030 (USD Million) 9. Market: By End-user Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Academic Research Institutes 9.3.1. Academic Research Institutes market, 2021 - 2030 (USD Million) 9.4. Biotechnology companies 9.4.1. Biotechnology companies market, 2021 - 2030 (USD Million) 9.5. Government Research Institutes 9.5.1. Government Research Institutes market, 2021 - 2030 (USD Million) 9.5. Pharmaceutical companies 9.5.1. Pharmaceutical companies market, 2021 - 2030 (USD Million) 10. Market: By Application Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Cell Line Engineering 10.3.1. Cell Line Engineering market, 2021 - 2030 (USD Million) 10.4. Diagnostic applications 10.4.1. Diagnostic applications market, 2021 - 2030 (USD Million) 10.5. Drug discovery and development 10.5.1. Drug discovery and development Market, 2021 - 2030 (USD Million) 10.6. Plant Genetic Engineering 10.6.1. Plant Genetic Engineering Market, 2021 - 2030 (USD Million) 10.6. Animal Genetic Engineering 10.6.1. Animal Genetic Engineering Market, 2021 - 2030 (USD Million) 10.6. Other applications 10.6.1. Other applications Market, 2021 - 2030 (USD Million) 11. Market: Regional Outlook 11.1 North America 11.1.1. North America market, By Product and Service, 2021 - 2030 (USD Million) 11.1.2. North America market, By Technology, 2021 - 2030 (USD Million) 11.1.3. North America market, by Application, 2021 - 2030 (USD Million) 11.1.4. North America market, by Country, 2021 - 2030 (USD Million) 11.1.5. North America market, By Type, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. market, By Product and Service, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. market, By Technology, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. market, by Application, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada market, By Product and Service, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada market, By Technology, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada market, by Application, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe market, By Product and Service, 2021 - 2030 (USD Million) 11.2.2. Europe market, By Technology, 2021 - 2030 (USD Million) 11.2.3. Europe market, by Application, 2021 - 2030 (USD Million) 11.2.4. Europe market, by country, 2021 - 2030 (USD Million) 11.2.5. Europe market, By Type, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. market, By Product and Service, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. market, By Technology, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. market, by Application, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany market, By Product and Service, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany market, By Technology, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany market, by Application, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France market, By Product and Service, 2021 - 2030 (USD Million) 11.2.4.3.2. France market, By Technology, 2021 - 2030 (USD Million) 11.2.4.3.3. France market, by Application, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe market, By Product and Service, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe market, By Technology, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe market, by Application, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific market, By Product and Service, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific market, By Technology, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific market, by Application, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.5. Asia Pacific market, By Type, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China market, By Product and Service, 2021 - 2030 (USD Million) 11.3.4.1.2. China market, By Technology, 2021 - 2030 (USD Million) 11.3.4.1.3. China market, by Application, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India market, By Product and Service, 2021 - 2030 (USD Million) 11.3.4.2.2. India market, By Technology, 2021 - 2030 (USD Million) 11.3.4.2.3. India market, by Application, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan market, By Product and Service, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan market, By Technology, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan market, by Application, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea market, By Product and Service, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea market, By Technology, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea market, by Application, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC market, By Product and Service, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC market, By Technology, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC market, by Application, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America market, By Product and Service, 2021 - 2030 (USD Million) 11.4.2. Latin America market, By Technology, 2021 - 2030 (USD Million) 11.4.3. Latin America market, by Application, 2021 - 2030 (USD Million) 11.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 11.4.5. Latin America market, By Type, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil market, By Product and Service, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil market, By Technology, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil market, by Application, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico market, By Product and Service, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico market, By Technology, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico market, by Application, 2021 - 2030 (USD Million) 11.4.4.3. Rest of Latin America 11.4.4.3.1. Rest of the Latin America market, By Product and Service, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America market, By Technology, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America market, by Application, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA market, By Product and Service, 2021 - 2030 (USD Million) 11.5.2. MEA market, By Technology, 2021 - 2030 (USD Million) 11.5.3. MEA market, by Application, 2021 - 2030 (USD Million) 11.5.4. MEA market, by region, 2021 - 2030 (USD Million) 11.5.5. MEA market, By Type, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 BEAM THERAPEUTICS 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Solutions Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Agilent Technologies 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Solutions Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Bluebird Bio 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Solutions Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. CARIBOU BIOSCIENCES 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Solutions Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. Beren Therapeutics 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Solutions Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Cellectis S.A 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Solutions Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. EDITAS MEDICINE 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Solutions Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. CREATIVE BIOGENE 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Solutions Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. Eurofins Scientific 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Solutions Portfolio Analysis 12.9.4. Business Strategy & Recent Development 12.10. CRISPR Therapeutics 12.10.1. Company overview 12.10.2. Financial performance 12.10.3. Solutions Portfolio Analysis 12.10.4. Business Strategy & Recent Development 12.11. Intellia Therapeutics 12.11.1. Company overview 12.11.2. Financial performance 12.11.3. Solutions Portfolio Analysis 12.11.4. Business Strategy & Recent Development 12.12. Horizon Discovery Group plc. 12.12.1. Company overview 12.12.2. Financial performance 12.12.3. Solutions Portfolio Analysis 12.12.4. Business Strategy & Recent Development 12.13. Integrated DNA Technologie 12.13.1. Company overview 12.13.2. Financial performance 12.13.3. Solutions Portfolio Analysis 12.13.4. Business Strategy & Recent Development 12.14. LONZA 12.14.1. Company overview 12.14.2. Financial performance 12.14.3. Solutions Portfolio Analysis 12.14.4. Business Strategy & Recent Development 12.15. GenScript 12.15.1. Company overview 12.15.2. Financial performance 12.15.3. Solutions Portfolio Analysis 12.15.4. Business Strategy & Recent Development 12.16. Merck 12.16.1. Company overview 12.16.2. Financial performance 12.16.3. Solutions Portfolio Analysis 12.16.4. Business Strategy & Recent Development 12.17. OriGene Technologies 12.17.1. Company overview 12.17.2. Financial performance 12.17.3. Solutions Portfolio Analysis 12.17.4. Business Strategy & Recent Development 12.18. New England Biolabs 12.18.1. Company overview 12.18.2. Financial performance 12.18.3. Solutions Portfolio Analysis 12.18.4. Business Strategy & Recent Development 12.19. Precision Biosciences 12.19.1. Company overview 12.19.2. Financial performance 12.19.3. Solutions Portfolio Analysis 12.19.4. Business Strategy & Recent Development 12.20. PerkinElmer 12.20.1. Company overview 12.20.2. Financial performance 12.20.3. Solutions Portfolio Analysis 12.20.4. Business Strategy & Recent Development 12.21. Regeneron Pharmaceuticals 12.21.1. Company overview 12.21.2. Financial performance 12.21.3. Solutions Portfolio Analysis 12.21.4. Business Strategy & Recent Development 12.22. Recombinetics 12.22.1. Company overview 12.22.2. Financial performance 12.22.3. Solutions Portfolio Analysis 12.22.4. Business Strategy & Recent Development 12.23. Synthego 12.23.1. Company overview 12.23.2. Financial performance 12.23.3. Solutions Portfolio Analysis 12.23.4. Business Strategy & Recent Development 12.24. Sangamo Therapeutics 12.24.1. Company overview 12.24.2. Financial performance 12.24.3. Solutions Portfolio Analysis 12.24.4. Business Strategy & Recent Development 12.25. Thermo Fisher-Scientific 12.25.1. Company overview 12.25.2. Financial performance 12.25.3. Solutions Portfolio Analysis 12.25.4. Business Strategy & Recent Development 12.26. Vigene Biosciences 12.26.1. Company overview 12.26.2. Financial performance 12.26.3. Solutions Portfolio Analysis 12.26.4. Business Strategy & Recent Development 12.27. Tecan Life-Sciences 12.27.1. Company overview 12.27.2. Financial performance 12.27.3. Solutions Portfolio Analysis 12.27.4. Business Strategy & Recent Development 12.28. Trans-posagen Bio-pharmaceuticals 12.28.1. Company overview 12.28.2. Financial performance 12.28.3. Solutions Portfolio Analysis 12.28.4. Business Strategy & Recent Development List of Tables (97 Tables) TABLE 1. MARKET, By Product and Service, 2021-2030 (USD Million) TABLE 2. MARKET FOR Consumables, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Reagents, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Services, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Software, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Systems, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET, By Technology, 2021-2030 (USD Million) TABLE 8. MARKET FOR Antisense, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR CRISPR, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR TALEN, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR ZFN, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Other technologies, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Cell Line Engineering, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Diagnostic applications, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Drug discovery and development, BY REGION, 2021-2030 (USD Million) TABLE17 MARKET FOR Plant Genetic Engineering, BY REGION, 2021-2030 (USD Million) TABLE18. MARKET FOR Animal Genetic Engineering, BY REGION, 2021-2030 (USD Million) TABLE19. MARKET FOR Other applications, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET, By End-user, 2021-2030 (USD Million) TABLE 21. MARKET FOR Academic Research Institutes, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET FOR Biotechnology companies, BY REGION, 2021-2030 (USD Million) TABLE 23. MARKET FOR Government Research Institutes, BY REGION, 2021-2030 (USD Million) TABLE 24. MARKET FOR Pharmaceutical companies, BY REGION, 2021-2030 (USD Million) TABLE 25. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 26. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 27. NORTH AMERICA MARKET, By Product and Service, 2021-2030 (USD Million) TABLE 28. NORTH AMERICA MARKET, By Technology, 2021-2030 (USD Million) TABLE 29. NORTH AMERICA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 30. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 31. EUROPE MARKET, By Product and Service, 2021-2030 (USD Million) TABLE 32. EUROPE MARKET, By Technology, 2021-2030 (USD Million) TABLE 33. EUROPE MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 34. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 35. ASIA-PACIFIC MARKET, By Product and Service, 2021-2030 (USD Million) TABLE 36. ASIA-PACIFIC MARKET, By Technology, 2021-2030 (USD Million) TABLE 37. ASIA-PACIFIC MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 38. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 39. LAMEA MARKET, By Product and Service, 2021-2030 (USD Million) TABLE 40. LAMEA MARKET, By End-user, 2021-2030 (USD Million) TABLE 41. LAMEA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 42. BEAM THERAPEUTICS: COMPANY SNAPSHOT TABLE 43. BEAM THERAPEUTICS: OPERATING SEGMENTS TABLE 44. Agilent Technologies: COMPANY SNAPSHOT TABLE 45. Agilent Technologies: OPERATING SEGMENTS TABLE 46. Bluebird Bio: COMPANY SNAPSHOT TABLE 47. Bluebird Bio: OPERATING SEGMENTS TABLE 48. CARIBOU BIOSCIENCES: COMPANY SNAPSHOT TABLE 49. CARIBOU BIOSCIENCES: OPERATING SEGMENTS TABLE 50. Beren Therapeutics: COMPANY SNAPSHOT TABLE 51. Beren Therapeutics: OPERATING SEGMENTS TABLE 52. Cellectis S.A: COMPANY SNAPSHOT TABLE 53. Cellectis S.A: OPERATING SEGMENTS TABLE 54. EDITAS MEDICINE: COMPANY SNAPSHOT TABLE 55. EDITAS MEDICINE: OPERATING SEGMENTS TABLE 56. CREATIVE BIOGENE: COMPANY SNAPSHOT TABLE 57. CREATIVE BIOGENE: OPERATING SEGMENTS TABLE 58. Eurofins Scientific: COMPANY SNAPSHOT TABLE 59. Eurofins Scientific: OPERATING SEGMENTS TABLE 60. CRISPR Therapeutics : COMPANY SNAPSHOT TABLE 61. CRISPR Therapeutics : OPERATING SEGMENTS TABLE 62. Intellia Therapeutics: COMPANY SNAPSHOT TABLE 63. Intellia Therapeutics: OPERATING SEGMENTS TABLE 64. Horizon Discovery Group plc.: COMPANY SNAPSHOT TABLE 65. Horizon Discovery Group plc.: OPERATING SEGMENTS TABLE 66. Integrated DNA Technologie: COMPANY SNAPSHOT TABLE 67. Integrated DNA Technologie: OPERATING SEGMENTS TABLE 68. LONZA: COMPANY SNAPSHOT TABLE 69. LONZA: OPERATING SEGMENTS TABLE 70. GenScript : COMPANY SNAPSHOT TABLE 71. GenScript : OPERATING SEGMENTS TABLE 72. Merck: COMPANY SNAPSHOT TABLE 73. Merck: OPERATING SEGMENTS TABLE 74. OriGene Technologies: COMPANY SNAPSHOT TABLE 75. OriGene Technologies: OPERATING SEGMENTS TABLE 76. New England Biolabs: COMPANY SNAPSHOT TABLE 77. New England Biolabs: OPERATING SEGMENTS TABLE 78. Precision Biosciences: COMPANY SNAPSHOT TABLE 79. Precision Biosciences: OPERATING SEGMENTS TABLE 80. PerkinElmer: COMPANY SNAPSHOT TABLE 81. PerkinElmer: OPERATING SEGMENTS TABLE 82. Regeneron Pharmaceuticals: COMPANY SNAPSHOT TABLE 83. Regeneron Pharmaceuticals: OPERATING SEGMENTS TABLE 84. Recombinetics: COMPANY SNAPSHOT TABLE 85. Recombinetics: OPERATING SEGMENTS TABLE 86. Synthego: COMPANY SNAPSHOT TABLE 87. Synthego: OPERATING SEGMENTS TABLE 88. Sangamo Therapeutics: COMPANY SNAPSHOT TABLE 89. Sangamo Therapeutics: OPERATING SEGMENTS TABLE 90. Thermo Fisher-Scientific: COMPANY SNAPSHOT TABLE 91. Thermo Fisher-Scientific: OPERATING SEGMENTS TABLE 92. Vigene Biosciences: COMPANY SNAPSHOT TABLE 93. Vigene Biosciences: OPERATING SEGMENTS TABLE 94. Tecan Life-Sciences: COMPANY SNAPSHOT TABLE 95. Tecan Life-Sciences: OPERATING SEGMENTS TABLE 96. Trans-posagen Bio-pharmaceuticals: COMPANY SNAPSHOT TABLE 97. Trans-posagen Bio-pharmaceuticals: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product and Service-Based Estimation Figure 6 Top 28 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Genome Editing, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Genome Editing, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Technology, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product and Service, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Cell Line Engineering to Witness Higher CAGR in the Market for Application Segment during the Forecast Period. Figure 17 Biotechnology and pharmaceutical to Witness Higher CAGR in Market for End-user Driving during Forecast Period. Figure 17 CRISPR to Witness Higher CAGR in Market for Technology Driving during Forecast Period. Figure 17 Reagents and consumables to Witness Higher CAGR in Market for Product and Service Driving during Forecast Period. Figure 18 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview